2013
DOI: 10.1093/brain/awt164
|View full text |Cite
|
Sign up to set email alerts
|

Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: potential role in reinnervation ability and disease progression

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

6
100
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 121 publications
(106 citation statements)
references
References 30 publications
6
100
0
Order By: Relevance
“…Indeed, numerous studies showed that degeneration and loss of motor neurons followed by structural and functional changes in innervations, significantly contribute to the progression of sarcopenia [50][51][52]. Considering the central role in mediating skeletal muscle nerve response, several studies indicated HDAC4 as a potential therapeutic target for the prevention of neurogenic muscle atrophy in pathological conditions or during aging [38,53]. In all these conditions, the proposed treatments should be prolonged for months or years.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Indeed, numerous studies showed that degeneration and loss of motor neurons followed by structural and functional changes in innervations, significantly contribute to the progression of sarcopenia [50][51][52]. Considering the central role in mediating skeletal muscle nerve response, several studies indicated HDAC4 as a potential therapeutic target for the prevention of neurogenic muscle atrophy in pathological conditions or during aging [38,53]. In all these conditions, the proposed treatments should be prolonged for months or years.…”
Section: Discussionmentioning
confidence: 99%
“…Following denervation, HDAC4 indirectly regulates myogenin expression, thereby connecting neuronal activity to skeletal muscle transcriptional reprogramming of the neuromuscular junctions and compensatory reinnervation [35]. Considering its crucial role, HDAC4 has been proposed as a potential therapeutic target for diseases characterized by neurogenic muscle atrophy, such as ALS or SMA, or for sarcopenia [36][37][38][39]. Any pharmacological treatment with HDAC4 inhibitors for these conditions should be continued for months or years.…”
Section: Introductionmentioning
confidence: 99%
“…In patients with ALS, the upregulation of HDAC4 in skeletal muscle is associated with muscle denervation [35]. Additionally, HDAC4 has been related to fibrosis [36]; Barbier-Torres et al [37] showed that HDAC4 expression promoted cholestatic liver injury and alleviated liver fibrosis in mice.…”
Section: Discussionmentioning
confidence: 99%
“…These drugs include HDAC inhibitors [101] and HMT inhibitors alone [102] or in combination [103] . In amyotrophic lateral sclerosis, HDAC inhibitors have been proposed as potential drugs to ameliorate patient symptoms [104,105] . In the case of muscular dystrophy, HDAC inhibitors have been extensively studied using the mdx mouse model [106] ; currently, these drugs are under review in a clinical trial for muscular dystrophy [107] .…”
Section: Resultsmentioning
confidence: 99%